ImmuPharma plc (LON:IMM – Get Free Report) shares were down 18% during mid-day trading on Monday . The company traded as low as GBX 3.52 and last traded at GBX 3.60. 1,204,775 shares were traded during mid-day trading, a decline of 53% from the average session volume of 2,577,156 shares. The stock had previously closed at GBX 4.39.
ImmuPharma Price Performance
The stock has a market capitalization of £22.46 million, a P/E ratio of -9.73 and a beta of 3.02. The firm has a 50-day simple moving average of GBX 4.10 and a 200 day simple moving average of GBX 5.05.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
- D-Wave Has Momentum—What Does It Need to Keep It Going?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
